Blood tests and lung scans to predict biologic therapy success
Part of Lungs & breathing clinical trials.
This study uses blood tests and lung imaging to predict how well biologic medications work for severe eosinophilic asthma-COPD overlap. If you're starting a biologic treatment, researchers want to understand which patients benefit most and why.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 14 or older
- Your doctor has decided to start you on one of three biologic medications: benralizumab, mepolizumab, or dupilumab
- Your blood eosinophil count (a type of white blood cell) is at least 150 per microliter within the past 3 months, or at least 300 within the past year
- You have not received biologic treatment for asthma-COPD overlap before
- You are not currently enrolled in another treatment study
- You do not have active cancer or a history of cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a specific “signature” from asthma tests can predict who will respond to benralizumab (a severe asthma biologic). If you qualify, the researchers will compare your test results to how well benralizumab controls your asthma and prevents flare-ups.
This study looks at how well different biologic treatments work for people with severe or mild-to-moderate asthma, and compares them to healthy volunteers. It aims to find which treatments work best for different asthma types.
This study tests a new way to monitor severe asthma that is driven by high levels of inflammation (T2-high). It involves a bronchoscopy (a thin tube to look inside your lungs) to see how well the treatment is working.
This study looks at whether asthma medications can reverse long-term lung damage. It uses special scans to see changes in your lungs over time. You may qualify if you have severe asthma and are starting a new biologic medicine, or if you are a healthy volunteer without lung disease.
This study tests if adding a new injectable medicine (benralizumab) to your current medium-dose inhaler works better than simply increasing your inhaler dose to control hard-to-treat asthma. It may help people with a specific type of asthma linked to high eosinophil levels.
This study looks at how certain immune cells (eosinophils) work in people with asthma. It compares people with mild to severe asthma, including those who have or haven't taken biologic treatments, against people without asthma. The goal is to better understand asthma and find new ways to treat it.
Hear when a new Severe Eosinophilic ACOS (Asthma-COPD Overlap) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.